Catalyst Event
Sino Biopharmaceutical Ltd (1177) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
5/29/2026, 12:00:00 AM
The company announced positive pivotal data from two Phase III clinical trials (B-Well 1 and B-Well 2) for bepirovirsen for the treatment of chronic hepatitis B, which were presented at the 2026 European Association for the Study of the Liver (EASL) Congress and published in the New England Journal of Medicine.
Korean Translation
만성 B형 간염 치료제 베피로비르센에 대한 두 건의 3상 임상시험(B-Well 1 및 B-Well 2)의 긍정적인 주요 데이터가 2026년 유럽간학회(EASL)에서 발표되고 뉴잉글랜드 저널 오브 메디슨에 게재되었음을 발표함.
Related Recent Events
Hanwha Corp (000880) · Trading Issue
Trading suspension for Hanwha Corp shares is scheduled to begin on 2026-07-30 in connection with the corporate spin-off, with trading expected to resume on 2026-08-25 upon relisting of Hanwha Corp and listing of the spun-off entity.
7/30/2026, 12:00:00 AM
Hanwha Corp (000880) · Trading Issue
Hanwha Corp confirmed a corporate spin-off creating Hanwha Machinery & Service Holdings (tentative name), separating the tech and life solutions businesses from the surviving Hanwha Corp, which will retain defense, energy, finance and related core businesses. The action also entails a scheduled trading suspension and distribution of new shares to existing holders.
7/30/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
The U.S. FDA's final decision on the New Drug Application (NDA) for the Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer is expected by the PDUFA date of July 23, 2026; this major binary event is expected to have a high price impact expected
7/23/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM